In yesterday’s Wall Street session, Merck & Co Inc (NYSE:MRK) shares traded at $102.95, down -1.29% from the previous session.
29 analysts cover Merck & Co Inc (NYSE:MRK), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $135.00 and a low of $103.00, we find $125.00. Given the previous closing price of $104.30, this indicates a potential upside of 19.85 percent. MRK stock price is now -4.34% away from the 50-day moving average and -6.28% away from the 200-day moving average. The market capitalization of the company currently stands at $261.24B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
The stock has received a hold rating from 9 analysts and a buy rating from 16. Brokers who have rated the stock have averaged $124.01 as their price target over the next twelve months.
With the price target of $123, HSBC Securities recently initiated with Hold rating for Merck & Co Inc (NYSE: MRK).
In other news, MIZELL STEVEN, EVP, Chief HR Officer sold 4,250 shares of the company’s stock on Aug 14. The stock was sold for $463,292 at an average price of $109.01. Upon completion of the transaction, the EVP, Chief HR Officer now directly owns 22,935 shares in the company, valued at $2.36 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 03, EVP, Chief HR Officer MIZELL STEVEN sold 4,500 shares of the business’s stock. A total of $474,701 was realized by selling the stock at an average price of $105.49. This leaves the insider owning 27,185 shares of the company worth $2.8 million. Insiders disposed of 3,634,535 shares of company stock worth roughly $374.18 million over the past 1 year. A total of 0.09% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MRK stock. A new stake in Merck & Co Inc shares was purchased by UNISUPER MANAGEMENT PTY LTD during the first quarter worth $117,485,000. HUDSON BAY CAPITAL MANAGEMENT LP invested $102,950,000 in shares of MRK during the first quarter. In the first quarter, NICHOLAS INVESTMENT PARTNERS, LP acquired a new stake in Merck & Co Inc valued at approximately $25,216,000. MARSHALL WACE, LLP acquired a new stake in MRK for approximately $18,128,000. GENUS CAPITAL MANAGEMENT INC. purchased a new stake in MRK valued at around $17,151,000 in the second quarter. In total, there are 4,093 active investors with 78.02% ownership of the company’s stock.
On Friday morning Merck & Co Inc (NYSE: MRK) stock kicked off with the opening price of $104.36. During the past 12 months, Merck & Co Inc has had a low of $86.02 and a high of $119.65. As of last week, the company has a debt-to-equity ratio of 0.95, a current ratio of 1.28, and a quick ratio of 1.03. According to the stock market information, the enterprise value for the company is $291.77B, which is based on a 84.77 price-to-earnings ratio, a 7.09 price-to-earnings-growth ratio, and a beta of 0.35. The fifty day moving average price for MRK is $107.52 and a two-hundred day moving average price translates $109.82 for the stock.
The latest earnings results from Merck & Co Inc (NYSE: MRK) was released for Jun, 2023. The net profit margin was 5.42% and return on equity was 7.59% for MRK. The company reported revenue of $15.04 billion for the quarter, compared to $14.59 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 3.03 percent.
Moreover, the firm recently paid out its quarterly dividend on 10/06/2023. Investors who held shares on 09/15/2023 were paid a $0.73 dividend. On an annualized basis, this represents a $2.97 dividend and a 2.88% percent yield. There was an ex-dividend date of 09/14/2023 for this dividend. In terms of dividend payout ratio, MRK is presently at 49.02%.
Merck & Co Inc(MRK) Company Profile
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
